



Formulary Focus

September 2019

MC-Rx's P&T Committee and team of dedicated clinicians have recommended the following changes to MC-Rx's National Formulary as of the effective dates shown. These decisions follow their clinical guidance and are based on safety, efficacy, side effect profile, and potential for abuse. While financial impact does not play a key role in the decision of coverage and preliminary placement, the ultimate cost of therapy of the selected products versus that of the other available products in the same therapeutic class is taken into consideration during final placement.

New BRAND Name Drug Additions to the Formulary

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Iron Preparations	Accrufer (ferric maltol)	Oral	Indicated for the treatment of iron deficiency in adults.	Tier 3 P/A	9/1/19
Corticosteroids	Air Duo Digihaler (fluticasone propionate and salmeterol)	Inhalation	Indicated for treatment of asthma in patients aged 12 years and older.	Tier 3	9/1/19
Glycogenolytic Agent	Baqsimi (glucagon)	Nasal	Indicated for the treatment of severe hypoglycemia in patients with diabetes ages 4 years old and above.	Tier 3 QL 2/30	9/1/19
Vaccine	Dengvaxia (Dengue Tetravalent Vaccine)	Intramuscular	Indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4. For use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.	Tier 3 P/A	9/1/19
Calcium Channel Blocking Agents	Katerzia (amlodipine benzoate)	Oral	Calcium channel blocker that may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension and coronary artery disease.	Tier 3 P/A	9/1/19
Anticonvulsant Agent	Nayzilam (midazolam)	Nasal	Indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age or older.	Tier 3 P/A QL 1ml/30	9/1/19
Antineoplastic Agent	Nubeqa (darolutamide)	Oral (Specialty)	Indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.	Tier 2 P/A	9/1/19
Antineoplastic Agent	Piqray (alpelisib)	Oral (Specialty)	Indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive human epidermal growth factor receptor (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.	Tier 2 P/A	9/1/19
Antidiabetic Agent	Qternment XR (dapagliflozin saxagliptin, and metformin hcl)	Oral	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	Tier 2 P/A	9/1/19
Disease-Modifying Antirheumatic Agent	Rinvoq (upadacitinib)	Oral (Specialty)	Indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.	Tier 2 P/A	9/1/19
Cholinergic Agonist	Ruzurgi (amifampridine)	Oral	Indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.	Tier 3 P/A	9/1/19

New BRAND Name Drug Additions to the Formulary

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Contraceptive	Slynd (drospirenone)	Oral	Indicated for use by females of reproductive potential to prevent pregnancy.	Tier 3	9/1/19
Kidney Stone Agent	Thiola EC (tiopronin)	Oral	Indicated in combination with high fluid intake, alkali, and diet modification for the prevention of cystine stone formation in adults with pediatric patients 20kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.	Tier 3 P/A	9/1/19
Melanocortin Receptor Agonist	Vyleesi (bremelanotide)	Subcutaneous	Indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.	Tier 3 P/A	9/1/19
Protein Stabilizer	Vyndaqel (tafamidis medlumine)	Oral	Indicated for the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.	Tier 3 P/A	9/1/19
Anorexigenic Agent and stimulant	Wakix (pitolisant)	Oral	Indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.	Tier 3 P/A	9/1/19
Antibacterial	Xenleta (lefamulin)	Intravenous/ Oral	Indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible micro-organism: streptococcus pneumoniae, staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenza, legionella pneumophila, mycoplasma pneumoniae, and Chlamydia pneumoniae.	Tier 3	9/1/19
Antineoplastic Agent	Xpovio (selinexor)	Oral (Specialty)	Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.	Tier 2 P/A	9/1/19

Medical Benefit

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Antineoplastic Agent	Kanjinti (trastuzumab-anns)	Intravenous	Indicated for treatment for breast cancer and gastric cancer.	Medical Benefit	9/1/19
Antineoplastic Agent	Polivy (polatuzumab vedotin-piiq)	Intravenous	Indicated for treatment for diffuse large B-cell lymphoma.	Medical Benefit	9/1/19
Antibiotic, Carbapenem	Recarbrio (imipenem, cilastatin, and relebactam)	Intravenous	Indicated for treatment for urinary tract infection and intra-abdominal infection.	Medical Benefit	9/1/19
Antineoplastic Agent, Monoclonal Antibody	Zirabev (bevacizumab-bvzr)	Intravenous	Indicated for treatment for colorectal cancer, non-small cell lung cancer, glioblastoma multiforme, renal cell carcinoma, and cervical cancer.	Medical Benefit	9/1/19
Gene Therapy, Adeno-Associated Virus	Zolgensma (onesemnogene abrparvovec-xioi)	Intravenous	Indicated for treatment for spinal muscular atrophy.	Medical Benefit	9/1/19
Antineoplastic Agent	Ruxience (rituximab-pvvr)	Intravenous	Indicated for treatment for Non-Hodgkin's lymphoma, CLL, and granulomatosis with polyangiitis (GPA).	Medical Benefit	9/1/19

Generic Releases & Updates Within the Next 90 Days

The following drugs are expected to lose their patents and become available generically within the next 90 days.

Uloric	Carnitor SF	
Hemabate	Zioptan	
Firazyr	Kuvan Powder for Oral Solution	
Lyrica (Capsules & Oral Solution)	Noxafil Tablets	
Rozerem	Orfadin Capsules	
Omidria	Soolantra	
Halog Cream		

Additional Notes

Copies of MC-Rx's National Formulary and Pocket Formulary can be found on our website, <http://www.mc-rx.com>, under the "PBM Resources/Drug and Formulary Lists" tab.